• The End of Covid Vaccines at ‘Warp Speed'

    11 days ago - By New York Times

    Financial and bureaucratic barriers in the United States mean that the next generation of Covid vaccines may well be designed here, but used elsewhere.
    Read more ...

     

  • Opinion: STAT+: Removing barriers to biosimilar adoption in the United States

    11 days ago - By STAT

    Biosimilars, a much-lauded approach to reducing drug costs in the United States, are still underused here, even as they are proving successful in Europe. Why? Two key reasons are misperceptions of inferiority and the intricacies of U.S. market access.
    As the head of U.S. market access for Samsung Bioepis, a South Korean developer and manufacturer of biosimilars, I routinely introduce our capabilities to key stakeholders in the U.S. health care market. Early after their introduction, the U.S. market showed little desire to embrace or use biosimilars. This sentiment largely held regardless...
    Read more ...